G1 Therapeutics, Inc. (GTHX) Tops Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
May 3, 2023 6:31 AM EDT- Drove 18% Quarterly Net Revenue Growth of COSELA® (trilaciclib) Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter -
- Provided Updated Timing for Interim Overall Survival (OS) Analysis of Pivotal Phase 3 Trial in Metastatic Triple Negative Breast Cancer (TNBC); Analysis Now Expected in the First Quarter of 2024 -
- Completed Enrollment in Phase 2 Trial of Trilaciclib in Combination with an Antibody Drug Conjugate (ADC) in Patients with Metastatic TNBC -
- Announced Acceptance of Additional Results from Phase 2 ADC and Neoadjuvant TNBC Trials... More
